drugset / Trial / NCT07214922
Relative Bioavailability of Evobrutinib Tablet Batches
Phase 1
Completed
28 enrolled
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
RandomizedCrossoverOpen-labelOther
Summary
The main purpose of the study is to compare the Pharmacokinetics (PK), safety and tolerability of different manufacturing batches of M2951 tablet formulation relative to a reference batch under fasted conditions in healthy participants.
Timeline
- Start
- 2023-01-18
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evobrutinib | Small molecule | — | Oral |
Indications
No indication recorded.